Last reviewed · How we verify
Acetazolamide-based medical therapy
Acetazolamide inhibits carbonic anhydrase to reduce aqueous humor production and cerebrospinal fluid formation, thereby lowering intraocular and intracranial pressure.
Acetazolamide inhibits carbonic anhydrase to reduce aqueous humor production and cerebrospinal fluid formation, thereby lowering intraocular and intracranial pressure. Used for Glaucoma and ocular hypertension, Idiopathic intracranial hypertension, High altitude cerebral edema.
At a glance
| Generic name | Acetazolamide-based medical therapy |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology, Neurology |
| Phase | Phase 3 |
Mechanism of action
Acetazolamide is a carbonic anhydrase inhibitor that decreases the production of aqueous humor in the eye and cerebrospinal fluid in the central nervous system by blocking the enzyme carbonic anhydrase. This leads to reduced intraocular pressure and intracranial pressure, making it useful in conditions where pressure reduction is therapeutic. The drug also has mild diuretic properties due to inhibition of renal carbonic anhydrase.
Approved indications
- Glaucoma and ocular hypertension
- Idiopathic intracranial hypertension
- High altitude cerebral edema
Common side effects
- Paresthesia (tingling in extremities)
- Altered taste (dysgeusia)
- Hypokalemia (low potassium)
- Metabolic acidosis
- Nephrolithiasis (kidney stones)
- Fatigue
Key clinical trials
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |